Evidence map›Paper›PMID 23756852›Full record

ArticlePflugers Archiv : European journal of physiology2013

Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6.

A L L Lameris, M W Hess, I van Kruijsbergen, J G J Hoenderop, R J M Bindels

Registry-linked trialOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02518659 (Inulin- a Potential Preventive Dietary Supplement Against PPI Induced Hypomagnesemia), which is not on this map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02518659 nacompletednot on this mapstarted 2014, after this paper: background citation

Inulin- a Potential Preventive Dietary Supplement Against PPI Induced Hypomagnesemia

TypeinterventionalSponsorRadboud University Medical CenterRan2014 to 2015Enrolled21ConditionsHypomagnesemia, Intestinal, With Secondary Hypocalcemia, Drug Induced HypomagnesemiaArmsInulin
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Mechanisms of proton pump inhibitor-induced hypomagnesemia.Acta physiologica (Oxford, England) · 2022
    Review
  12. Increased colonic KScientific reports · 2021
    Article
  13. Review
  14. Article
  15. Article
  16. The Perilous PPI: Proton Pump Inhibitor as a Cause of Clinically Significant Hypomagnesaemia.Journal of the ASEAN Federation of Endocrine Societies · 2020
    Article
  17. Review
  18. Review
  19. The inhibitory role of purinergic P2Y receptor on MgThe journal of physiological sciences : JPS · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

A L L LamerisDepartment of Physiology, Nijmegen Centre for Molecular Life Science, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
M W Hess
I van Kruijsbergen
J G J Hoenderop
R J M Bindels
Radboud University Nijmegen · NLRadboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, used by millions of patients suffering from gastric acid-related complaints. Although PPIs have an excellent safety profile, an increasing number of case reports describe patients with severe hypomagnesemia due to long-term PPI use. As there is no evidence of a renal Mg²⁺ leak, PPI-induced hypomagnesemia is hypothesized to result from intestinal malabsorption of Mg²⁺. The aim of this study was to investigate the effect of PPIs on Mg ²⁺homeostasis in an in vivo mouse model. To this end, C57BL/6J mice were treated with omeprazole, under normal and low dietary Mg²⁺ availability. Omeprazole did not induce changes in serum Mg²⁺ levels (1.48 ± 0.05 and 1.54 ± 0.05 mmol/L in omeprazole-treated and control mice, respectively), urinary Mg²⁺ excretion (35 ± 3 μmol/24 h and 30 ± 4 μmol/24 h in omeprazole-treated and control mice, respectively), or fecal Mg²⁺ excretion (84 ± 4 μmol/24 h and 76 ± 4 μmol/24 h in omeprazole-treated and control mice, respectively) under any of the tested experimental conditions. However, omeprazole treatment did increase the mRNA expression level of the transient receptor potential melastatin 6 (TRPM6), the predominant intestinal Mg²⁺ channel, in the colon (167 ± 15 and 100 ± 7 % in omeprazole-treated and control mice, respectively, P < 0.05). In addition, the expression of the colonic H⁺,K⁺-ATPase (cHK-α), a homolog of the gastric H⁺,K⁺-ATPase that is the primary target of omeprazole, was also significantly increased (354 ± 43 and 100 ± 24 % in omeprazole-treated and control mice, respectively, P < 0.05). The expression levels of other magnesiotropic genes remained unchanged. Based on these findings, we hypothesize that omeprazole inhibits cHK-α activity, resulting in reduced extrusion of protons into the large intestine. Since TRPM6-mediated Mg²⁺absorption is stimulated by extracellular protons, this would diminish the rate of intestinal Mg²⁺ absorption. The increase of TRPM6 expression in the colon may compensate for the reduced TRPM6 currents, thereby normalizing intestinal Mg²⁺ absorption during omeprazole treatment in C57BL/6J mice, explaining unchanged serum, urine, and fecal Mg²⁺ levels.

Indexed as

AnimalsColonH(+)-K(+)-Exchanging ATPaseHomeostasisIntestinal AbsorptionMagnesiumMiceMice, Inbred C57BLOmeprazoleProton Pump InhibitorsRNA, MessengerTranscription, GeneticTRPM Cation ChannelsH(+)-K(+)-Exchanging ATPaseMagnesiumOmeprazoleProton Pump InhibitorsRNA, MessengerTrpm6 protein, mouseTRPM Cation Channels

Identifiers

PMID23756852
OpenAlexW2144732891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.